Search

Your search keyword '"Enterocolitis, Pseudomembranous prevention & control"' showing total 667 results

Search Constraints

Start Over You searched for: Descriptor "Enterocolitis, Pseudomembranous prevention & control" Remove constraint Descriptor: "Enterocolitis, Pseudomembranous prevention & control"
667 results on '"Enterocolitis, Pseudomembranous prevention & control"'

Search Results

101. The role of Gr-1(+) cells and tumour necrosis factor-α signalling during Clostridium difficile colitis in mice.

102. Saccharomyces boulardii for the prevention of hospital onset Clostridium difficile infection.

103. Stopping the spread of C. diff.

104. An agent-based simulation model for Clostridium difficile infection control.

105. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.

106. Chlorhexidine bathing and health care-associated infections: a randomized clinical trial.

107. Novel risk factors for recurrent Clostridium difficile infection in children.

108. Probiotics for antibiotic-associated diarrhea: do we have a verdict?

109. Europe-wide call to combat c. difficile.

110. Outbreak of Clostridium difficile ribotype 027 in a residential home.

112. Modern trends in infection control practices in intensive care units.

113. Risk of AKI with gentamicin as surgical prophylaxis.

114. Systemically administered IgG anti-toxin antibodies protect the colonic mucosa during infection with Clostridium difficile in the piglet model.

115. Exogenous phosphatidylcholine supplementation improves intestinal barrier defense against Clostridium difficile toxin.

116. Lessons learned from implementing Clostridium difficile-focused antibiotic stewardship interventions.

117. A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice.

118. Clostridium difficile: improving the prevention paradigm in healthcare settings.

119. Use of data envelopment analysis to quantify opportunities for antibacterial targets for reduction of health care-associated Clostridium difficile infection.

120. Fidaxomicin: a novel macrolide antibiotic for Clostridium difficile infection.

121. Clostridium difficile infections in Veterans Health Administration acute care facilities.

122. Asymptomatic Clostridium difficile colonization as a reservoir for Clostridium difficile infection.

123. Clostridium difficile infection: nursing considerations.

126. Clostridium difficile infection.

128. The effect of pharmacy restriction of clindamycin on Clostridium difficile infection rates in an orthopedics ward.

130. Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.

131. Antibiotic-associated complications following lower limb arthroplasty: a comparison of two prophylactic regimes.

132. Clostridium difficile infections in HIV-positive patients with diarrhoea.

133. Reduction in the incidence of hospital-acquired Clostridium difficile infection through infection control interventions other than the restriction of antimicrobial use.

134. Role of the intestinal microbiota in resistance to colonization by Clostridium difficile.

135. [Saccharomyces boulardii in the treatment and prevention of antibiotic-associated diarrhea].

136. Control of Clostridium difficile infection in the hospital setting.

137. Variability of contact precaution policies in US emergency departments.

138. A randomized trial of soap and water hand wash versus alcohol hand rub for removal of Clostridium difficile spores from hands of patients.

139. An examination of longitudinal CAUTI, SSI, and CDI rates from key HHS data systems.

140. Probiotics and antibiotic-associated diarrhoea - Authors' reply.

141. Probiotics and antibiotic-associated diarrhoea.

142. Probiotics and antibiotic-associated diarrhoea.

144. FDA grants Fast Track designation for Pfizer’s C. diff vaccine candidate.

145. The roles of toxin A and toxin B in Clostridium difficile infection: insights from the gnotobiotic piglet model.

146. A mathematical model to evaluate the routine use of fecal microbiota transplantation to prevent incident and recurrent Clostridium difficile infection.

148. Parameters for the mathematical modelling of Clostridium difficile acquisition and transmission: a systematic review.

149. Practicing prevention with probiotics.

150. A high-dose preparation of lactobacilli and bifidobacteria in the prevention of antibiotic-associated and Clostridium difficile diarrhoea in older people admitted to hospital: a multicentre, randomised, double-blind, placebo-controlled, parallel arm trial (PLACIDE).

Catalog

Books, media, physical & digital resources